Targeted cancer therapies are an expanding field of effective therapeutic approaches. While previous chemotherapy agents indiscriminately killed rapidly proliferating cells, newer “precision medicine” ...
A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, ...
(a) Schematic of IHoM and IHeM models. NC: neutral cells; AC: cells carrying antigen mutations; IC: immune-recognizable cells; EC: immune-escaped cells. (b) Response of IHoM and IHeM to monotherapies ...
Visualization in the UMAP space of samples corresponding to the subtypes ER+ (a), HER2+ (b), and TN (c). The samples were categorized by cancer subtype and integrated. Cells are color-coded according ...
What innovative approaches in imaging are you seeing advancing immuno-oncology? Two innovations stand out, and they are not mutually exclusive. Molecular imaging, such as PET, utilizes specific ...
Extrachromosomal DNAs (ecDNAs) are circular DNA structures located in the nuclei of cells outside chromosomes. They were originally discovered in chromosome spreads of cells obtained from embryonal ...
Mutation profiling of appendiceal cancer: Distinguishing tumor grades, comprehensive mutation landscape, and ctDNA as a discovery tool. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility Bispecific antibodies (bsAbs) have emerged as a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results